Receipts
Every source, in one place.
148 citations: peer-reviewed studies, federal agencies, laws, and reputable reporting. Click any number on the site to jump here.
Links checked November 14, 2026. A few government and news sites block automated checkers, but they open normally in a browser.
- 1Peer-reviewed studyLachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Scientific Reports. 2015;5:8126. doi:10.1038/srep08126
https://www.nature.com/articles/srep08126 - 2Peer-reviewed studyNutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010;376(9752):1558–1565. PMID 21036393
https://pubmed.ncbi.nlm.nih.gov/21036393/ - 3Government dataCenters for Disease Control and Prevention. Facts About U.S. Deaths from Excessive Alcohol Use.
https://www.cdc.gov/alcohol/facts-stats/index.html - 4Government reportEsser MB, Sherk A, Liu Y, Naimi TS. Deaths from Excessive Alcohol Use — United States, 2016–2021. MMWR. 2024;73(8):154–161.
https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a1.htm - 5International agencyWorld Health Organization. Alcohol — fact sheet (data from the 2024 Global status report on alcohol and health).
https://www.who.int/news-room/fact-sheets/detail/alcohol - 6Peer-reviewed studyGBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016. The Lancet. 2018;392:1015–1035. PMID 30146330
https://pubmed.ncbi.nlm.nih.gov/30146330/ - 7Government reportU.S. Surgeon General. Alcohol and Cancer Risk (Advisory), January 2025.
https://www.hhs.gov/surgeongeneral/reports-and-publications/alcohol-cancer/index.html - 8Peer-reviewed studyLopez-Quintero C, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the NESARC. Drug and Alcohol Dependence. 2011;115(1-2):120–130. PMID 21145178
https://pubmed.ncbi.nlm.nih.gov/21145178/ - 9Systematic review & meta-analysisLeung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? Addictive Behaviors. 2020;109:106479. PMID 32485547
https://pubmed.ncbi.nlm.nih.gov/32485547/ - 10National Academies reportNational Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017.
https://www.nationalacademies.org/publications/24625 - 11National Academies reportNASEM (2017). Report in brief: Committee's conclusions (one-page list of all ~100 conclusions with evidence grades).
https://nap.nationalacademies.org/resource/24625/Cannabis_committee_conclusions.pdf - 12Government guidanceCenters for Disease Control and Prevention. Cannabis Health Effects.
https://www.cdc.gov/cannabis/health-effects/index.html - 13Peer-reviewed studyReiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduction Journal. 2009;6:35. PMID 19958538
https://pubmed.ncbi.nlm.nih.gov/19958538/ - 14Peer-reviewed studyLucas P, et al. Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada. International Journal of Drug Policy. 2020;86:102963. PMID 33068830
https://pubmed.ncbi.nlm.nih.gov/33068830/ - 15Peer-reviewed studyKaroly HC, et al. Effects of cannabis use on alcohol consumption in a sample of treatment-engaged heavy drinkers in Colorado. Addiction. 2021;116(9):2529–2537. PMID 33464670
https://pubmed.ncbi.nlm.nih.gov/33464670/ - 16Peer-reviewed reviewSubbaraman MS. Can cannabis be considered a substitute medication for alcohol? Alcohol and Alcoholism. 2014;49(3):292–298. PMID 24402247
https://pubmed.ncbi.nlm.nih.gov/24402247/ - 17Peer-reviewed studyShover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. PNAS. 2019;116(26):12624–12626. PMID 31182592
https://pubmed.ncbi.nlm.nih.gov/31182592/ - 18Peer-reviewed studyWang M, et al. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using UHPSFC/PDA-MS. Cannabis and Cannabinoid Research. 2016;1(1):262–271. PMID 28861498
https://pubmed.ncbi.nlm.nih.gov/28861498/ - 19Peer-reviewed reviewMoreno-Sanz G. Can You Pass the Acid Test? Critical Review and Novel Therapeutic Perspectives of Δ9-Tetrahydrocannabinolic Acid A. Cannabis and Cannabinoid Research. 2016;1(1):124–130. PMID 28861488
https://pubmed.ncbi.nlm.nih.gov/28861488/ - 20Systematic review & meta-analysisWhiting PF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. PMID 26103030
https://pubmed.ncbi.nlm.nih.gov/26103030/ - 21Government guidanceU.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process.
https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process - 22Randomized controlled trialDevinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376:2011–2020. PMID 28538134
https://pubmed.ncbi.nlm.nih.gov/28538134/ - 23Peer-reviewed studyMeier MH, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. PNAS. 2012;109(40):E2657–E2664. PMID 22927402
https://pubmed.ncbi.nlm.nih.gov/22927402/ - 24Systematic reviewSorensen CJ, et al. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment — a Systematic Review. Journal of Medical Toxicology. 2017;13(1):71–87. PMID 28000146
https://pubmed.ncbi.nlm.nih.gov/28000146/ - 25Peer-reviewed reviewHartman RL, Huestis MA. Cannabis effects on driving skills. Clinical Chemistry. 2013;59(3):478–492. PMID 23220273
https://pubmed.ncbi.nlm.nih.gov/23220273/ - 26Government guidanceCenters for Disease Control and Prevention. Cannabis and Poisoning.
https://www.cdc.gov/cannabis/health-effects/poisoning.html - 27Government guidanceHealth Canada. What you need to know if you choose to consume cannabis. 2019.
https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/resources/what-you-need-to-know-if-you-choose-to-consume-cannabis.html - 28Government guidanceCenters for Disease Control and Prevention. Cannabis and Pregnancy.
https://www.cdc.gov/cannabis/health-effects/pregnancy.html - 29Federal law7 U.S.C. § 1639o — Definitions (hemp), including the 2025 amendment and its effective-date notes.
https://uscode.house.gov/us/usc/119-142/t7/s1639o/ - 30Congressional Research ServiceCongressional Research Service. Change to Federal Definition of Hemp and Implications for Federal Enforcement (IN12620).
https://www.congress.gov/crs-product/IN12620 - 31Legal analysisWomble Bond Dickinson (via JD Supra). Hemp Restrictions Start November 12, 2026, but Key Questions Remain. Nov 13, 2026.
https://www.jdsupra.com/legalnews/hemp-restrictions-start-november-12-1243411/ - 32State government guidanceIowa HHS. Consumable Hemp — Federal Hemp Law Changes & FAQs (summarizes the Nov 12 and Dec 11, 2026 federal dates).
https://hhs.iowa.gov/health-prevention/consumable-hemp/consumable-hemp-federal-hemp-law-changes-faqs - 33Federal RegisterDOJ final rule: Rescheduling of FDA-Approved Products Containing Marijuana (and marijuana under a state medical license) From Schedule I to Schedule III. 91 FR, April 28, 2026.
https://www.federalregister.gov/documents/2026/04/28/2026-08176/schedules-of-controlled-substances-rescheduling-of-food-and-drug-administration-approved-products - 34Government press releaseU.S. Department of Justice. Justice Department Announces Issuance of Federal Registrations for Medical Marijuana Dispensaries.
https://www.justice.gov/opa/pr/justice-department-announces-issuance-federal-registrations-medical-marijuana-dispensaries - 35Government pageU.S. Drug Enforcement Administration. Marijuana Rescheduling Regulatory Actions.
https://www.dea.gov/marijuana-rescheduling-regulatory-actions - 36State government guidanceTennessee Alcoholic Beverage Commission. Frequently Asked Questions — hemp-derived cannabinoid regulation (Public Chapter 526, 2025).
https://www.tn.gov/abc/public-information-and-forms/frequently-asked-questions.html - 37State legislationTennessee General Assembly. HB1376 / SB1413 (114th GA) — bill history and amendments (became Public Chapter 526).
https://wapp.capitol.tn.gov/apps/BillInfo/Default?BillNumber=HB1376&ga=114 - 38News reportWKRN/WATE. TN law banning THCA products takes full effect July 1 (2026).
https://www.wate.com/news/tennessee/tennessees-thca-ban-to-take-full-effect-july-1/ - 39News reportNewsChannel 5 Nashville. New Tennessee hemp laws take effect July 1 (2026).
https://www.newschannel5.com/news/state/tennessee/davidson-county/new-tennessee-hemp-laws-take-effect-july-1-causing-some-businesses-to-close-relocate-or-adapt - 40State lawTenn. Code Ann. § 39-17-418 — Simple possession or casual exchange.
https://law.justia.com/codes/tennessee/title-39/chapter-17/part-4/section-39-17-418/ - 41Legal referenceFindLaw. Tennessee Marijuana Laws.
https://www.findlaw.com/state/tennessee-law/tennessee-marijuana-laws.html - 42Government health referenceMedlinePlus (U.S. National Library of Medicine). Alcohol withdrawal.
https://medlineplus.gov/ency/article/000764.htm - 43Randomized placebo-controlled trialNaftali T, et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276–1280. PMID 23648372
https://pubmed.ncbi.nlm.nih.gov/23648372/ - 44Prospective studyBonn-Miller MO, et al. The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder. Cannabis and Cannabinoid Research. 2022;7(2):214–223. PMID 33998874
https://pubmed.ncbi.nlm.nih.gov/33998874/ - 45Systematic reviewOrsolini L, et al. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. Medicina. 2019;55(9):525. PMID 31450833
https://pubmed.ncbi.nlm.nih.gov/31450833/ - 46Peer-reviewed study (preclinical)Nadal X, et al. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. British Journal of Pharmacology. 2017;174(23):4263–4276. PMID 28853159
https://pubmed.ncbi.nlm.nih.gov/28853159/ - 47Peer-reviewed study (preclinical)Rock EM, et al. Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. British Journal of Pharmacology. 2013;170(3):641–648. PMID 23889598
https://pubmed.ncbi.nlm.nih.gov/23889598/ - 48Peer-reviewed study (preclinical, NIH)Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. PNAS. 1998;95(14):8268–8273. PMID 9653176
https://pubmed.ncbi.nlm.nih.gov/9653176/ - 49U.S. patentU.S. Patent No. 6,630,507 B1, “Cannabinoids as antioxidants and neuroprotectants.” Assignee: United States of America as represented by the Department of Health and Human Services. Granted Oct 7, 2003.
https://patents.google.com/patent/US6630507 - 50Peer-reviewed studyBradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. JAMA Internal Medicine. 2018;178(5):667–672. PMID 29610897
https://pubmed.ncbi.nlm.nih.gov/29610897/ - 51Peer-reviewed studyLucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy. 2017;42:30–35. PMID 28189912
https://pubmed.ncbi.nlm.nih.gov/28189912/ - 52Peer-reviewed studyLucas P, et al. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances. Harm Reduction Journal. 2019;16:9. PMID 30691503
https://pubmed.ncbi.nlm.nih.gov/30691503/ - 53Peer-reviewed studyAnderson DM, Rees DI, Sabia JJ, Safford S. Association of Marijuana Legalization With Marijuana Use Among US High School Students, 1993–2019. JAMA Network Open. 2021;4(9):e2124638. PMID 34491352
https://pubmed.ncbi.nlm.nih.gov/34491352/ - 54Federal RegisterDOJ/DEA. Schedules of Controlled Substances: Rescheduling of Marijuana (proposed rule). 89 FR 44597, May 21, 2024.
https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana - 55Government reportHHS / FDA. Basis for the Recommendation to Reschedule Marijuana into Schedule III of the Controlled Substances Act (Aug 2023).
https://www.hhs.gov/sites/default/files/scheduling-recommendation.pdf - 56Civil-rights reportACLU. A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform (2020) — press release.
https://www.aclu.org/press-releases/new-aclu-report-despite-marijuana-legalization-black-people-still-almost-four-times - 57Advocacy-group tally of state dataMarijuana Policy Project. Cannabis Tax Revenue in States that Regulate Cannabis for Adult Use (compiled from state revenue reports).
https://www.mpp.org/assets/pdf/issues/legalization/cannabis-tax-revenue-states-regulate-cannabis-adult-use.pdf - 58Journalism (PBS)PBS FRONTLINE. Marijuana Timeline — “Busted: America's War on Marijuana.”
https://www.pbs.org/wgbh/pages/frontline/shows/dope/etc/cron.html - 59JournalismAdams C. The man behind the marijuana ban for all the wrong reasons. CBS News, Nov 17, 2016.
https://www.cbsnews.com/news/harry-anslinger-the-man-behind-the-marijuana-ban/ - 60Primary sourceAnslinger HJ, Cooper CR. “Marijuana — Assassin of Youth.” The American Magazine, July 1937 (condensed in Reader's Digest, Feb 1938; transcription at the Schaffer Library). Archived copy at the Internet Archive; alternate transcription: druglibrary.net
https://web.archive.org/web/20210211181216/http://druglibrary.org/mags/assassinofyouth.htm - 61Scholarly historyBonnie RJ, Whitebread CH. The Marihuana Conviction: A History of Marihuana Prohibition in the United States — chapter “Nonchalance on Capitol Hill” (1937 hearings and Dr. William Woodward's AMA testimony).
https://www.drugtext.org/library/cannabis/the-marihuana-conviction/nonchalance-on-capitol-hill - 62JournalismSullum J. 50 Years After Nixon's Commission Said Cops Should Stop Busting Pot Users... Reason, Mar 22, 2022 (quotes the 1972 Shafer Commission report).
https://reason.com/2022/03/22/50-years-after-nixons-commission-said-cops-should-stop-busting-pot-users-the-federal-ban-remains-unchanged/ - 63JournalismBaum D. Legalize It All. Harper's Magazine, April 2016.
https://harpers.org/archive/2016/04/legalize-it-all/ - 64JournalismCNN. Report: Nixon aide says war on drugs targeted blacks, hippies. Mar 23, 2016 (includes the Ehrlichman family's response).
https://www.cnn.com/2016/03/23/politics/john-ehrlichman-richard-nixon-drug-war-blacks-hippie - 65JournalismIngraham C. A maker of deadly painkillers is bankrolling the opposition to legal marijuana in Arizona. Washington Post, Sep 9, 2016.
https://www.washingtonpost.com/news/wonk/wp/2016/09/09/a-maker-of-deadly-painkillers-is-bankrolling-the-opposition-to-legal-marijuana-in-arizona/ - 66JournalismPhoenix New Times. Arizona Drug Firm Insys Makes Synthetic Pot Compound, Spends Big to Defeat Legal Pot. 2016.
https://www.phoenixnewtimes.com/news/arizona-drug-firm-insys-makes-synthetic-pot-compound-spends-big-to-defeat-legal-pot-8628614/ - 67Government press releaseU.S. Attorney's Office, District of Massachusetts. Founder and Four Executives of Insys Therapeutics Convicted of Racketeering Conspiracy. May 2, 2019.
https://www.justice.gov/usao-ma/pr/founder-and-four-executives-insys-therapeutics-convicted-racketeering-conspiracy - 68Journalism (campaign-finance records)WBUR. A Look At The Money For And Against Legalized Marijuana In Mass. Oct 20, 2016.
https://www.wbur.org/morningedition/2016/10/20/marijuana-ballot-question-money - 69JournalismNew York Magazine. Big Beer Takes on Little Weed at the Ballot Box. Sep 2016.
https://nymag.com/intelligencer/2016/09/big-beer-takes-on-little-weed-at-the-ballot-box.html - 70Journalism (campaign-finance records)Fang L. Police and Prison Guard Groups Fight Marijuana Legalization in California. The Intercept, May 18, 2016.
https://theintercept.com/2016/05/18/ca-marijuana-measure/ - 71Journalism (lobbying disclosures)Fang L. The Top Five Special Interest Groups Lobbying To Keep Marijuana Illegal. Republic Report, 2012.
https://www.republicreport.org/2012/marijuana-lobby-illegal/ - 72Government guidanceNational Institute on Drug Abuse. Cannabis (Marijuana) — research topic page (“Is cannabis a gateway drug?”).
https://nida.nih.gov/research-topics/cannabis-marijuana - 73Peer-reviewed studyBachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Internal Medicine. 2014;174(10):1668–1673. PMID 25154332
https://pubmed.ncbi.nlm.nih.gov/25154332/ - 74Peer-reviewed studyWen H, Hockenberry JM. Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees. JAMA Internal Medicine. 2018;178(5):673–679. PMID 29610827
https://pubmed.ncbi.nlm.nih.gov/29610827/ - 75Peer-reviewed studyBoehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. Journal of Pain. 2016;17(6):739–744. PMID 27001005
https://pubmed.ncbi.nlm.nih.gov/27001005/ - 76Peer-reviewed studyVigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLoS One. 2017;12(11):e0187795. PMID 29145417
https://pubmed.ncbi.nlm.nih.gov/29145417/ - 77Peer-reviewed studyLivingston MD, Barnett TE, Delcher C, Wagenaar AC. Recreational Cannabis Legalization and Opioid-Related Deaths in Colorado, 2000-2015. American Journal of Public Health. 2017;107(11):1827–1829. PMID 29019782
https://pubmed.ncbi.nlm.nih.gov/29019782/ - 78Peer-reviewed studyPowell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? Journal of Health Economics. 2018;58:29–42. PMID 29408153
https://pubmed.ncbi.nlm.nih.gov/29408153/ - 79Peer-reviewed studyCorroon JM Jr, Mischley LK, Sexton M. Cannabis as a substitute for prescription drugs – a cross-sectional study. Journal of Pain Research. 2017;10:989–998. PMID 28496355
https://pubmed.ncbi.nlm.nih.gov/28496355/ - 80Peer-reviewed studyHsu G, Kovács B. Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study. BMJ. 2021;372:m4957. PMID 33504472
https://pubmed.ncbi.nlm.nih.gov/33504472/ - 81Peer-reviewed studyShi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug and Alcohol Dependence. 2017;173:144–150. PMID 28259087
https://pubmed.ncbi.nlm.nih.gov/28259087/ - 82Peer-reviewed studyLopez CD, et al. State Medical Cannabis Laws Associated With Reduction in Opioid Prescriptions by Orthopaedic Surgeons in Medicare Part D Cohort. Journal of the American Academy of Orthopaedic Surgeons. 2021;29(4):e188–e197. PMID 32404683
https://pubmed.ncbi.nlm.nih.gov/32404683/ - 83Systematic reviewRisso C, Boniface S, Subbaraman MS, Englund A. Does cannabis complement or substitute alcohol consumption? A systematic review of human and animal studies. Journal of Psychopharmacology. 2020;34(9):938–954. PMID 32648806
https://pubmed.ncbi.nlm.nih.gov/32648806/ - 84Systematic reviewDe Aquino JP, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug and Alcohol Dependence. 2022;241:109702. PMID 36434879
https://pubmed.ncbi.nlm.nih.gov/36434879/ - 85Systematic review & meta-analysisCosta GPA, et al. The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies. American Journal of Drug and Alcohol Abuse. 2024;50(1):12–26. PMID 38225727
https://pubmed.ncbi.nlm.nih.gov/38225727/ - 86Randomized controlled trialMetrik J, Aston ER, Gunn RL, Swift R, MacKillop J, Kahler CW. Acute Effects of Cannabis on Alcohol Craving and Consumption: A Randomized Controlled Crossover Trial. American Journal of Psychiatry. 2026;183(2):134–143 (published online Nov 2025). PMID 41254853
https://pubmed.ncbi.nlm.nih.gov/41254853/ - 87Peer-reviewed studyBaggio M, Chong A, Kwon S. Marijuana and alcohol: Evidence using border analysis and retail sales data. Canadian Journal of Economics. 2020;53(2):563–591. doi:10.1111/caje.12437
https://doi.org/10.1111/caje.12437 - 88Government dataCenters for Disease Control and Prevention. Understanding the Opioid Overdose Epidemic.
https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html - 89Government dataNational Institute on Alcohol Abuse and Alcoholism. Alcohol Use Disorder (AUD) in the United States: Age Groups and Demographic Characteristics (2024 NSDUH data).
https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics - 90Randomized controlled trialThiele EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2018;391(10125):1085–1096. PMID 29395273
https://pubmed.ncbi.nlm.nih.gov/29395273/ - 91Randomized controlled trialDevinsky O, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine. 2018;378:1888–1897. PMID 29768152
https://pubmed.ncbi.nlm.nih.gov/29768152/ - 92Randomized controlled trialThiele EA, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurology. 2021;78(3):285–292. PMID 33346789
https://pubmed.ncbi.nlm.nih.gov/33346789/ - 93Randomized controlled trialGrimison P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology. 2020;31(11):1553–1560. PMID 32801017
https://pubmed.ncbi.nlm.nih.gov/32801017/ - 94Randomized controlled trialNovotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex) as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology. 2011;18(9):1122–1131. PMID 21362108
https://pubmed.ncbi.nlm.nih.gov/21362108/ - 95Randomized controlled trialAbrams DI, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–521. PMID 17296917
https://pubmed.ncbi.nlm.nih.gov/17296917/ - 96Randomized controlled trialWilsey B, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain. 2013;14(2):136–148. PMID 23237736
https://pubmed.ncbi.nlm.nih.gov/23237736/ - 97Randomized controlled trialBergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226. PMID 21307846
https://pubmed.ncbi.nlm.nih.gov/21307846/ - 98Randomized controlled trialWalsh JH, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021;44(11):zsab149. PMID 34115851
https://pubmed.ncbi.nlm.nih.gov/34115851/ - 99Peer-reviewed studyRhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. Pharmacotherapy. 2016;36(5):505–510. PMID 26749285
https://pubmed.ncbi.nlm.nih.gov/26749285/ - 100Peer-reviewed studyCuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and Long-Term Effects of Cannabis on Headache and Migraine. Journal of Pain. 2020;21(5-6):722–730. PMID 31715263
https://pubmed.ncbi.nlm.nih.gov/31715263/ - 101Randomized controlled trialNaftali T, et al. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial. Journal of Crohn's and Colitis. 2021;15(11):1799–1806. PMID 33858011
https://pubmed.ncbi.nlm.nih.gov/33858011/ - 102Peer-reviewed studyHabib G, Artul S. Medical Cannabis for the Treatment of Fibromyalgia. Journal of Clinical Rheumatology. 2018;24(5):255–258. PMID 29461346
https://pubmed.ncbi.nlm.nih.gov/29461346/ - 103Peer-reviewed studySinclair J, et al. Cannabis Use, a Self-Management Strategy Among Australian Women With Endometriosis: Results From a National Online Survey. Journal of Obstetrics and Gynaecology Canada. 2020;42(3):256–261. PMID 31722852
https://pubmed.ncbi.nlm.nih.gov/31722852/ - 104Peer-reviewed studyBar-Lev Schleider L, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Internal Medicine. 2018;49:37–43. PMID 29482741
https://pubmed.ncbi.nlm.nih.gov/29482741/ - 105Executive orderThe White House. Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research. December 18, 2025.
https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/ - 106Peer-reviewed reviewLu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry. 2016;79(7):516–525. PMID 26698193
https://pubmed.ncbi.nlm.nih.gov/26698193/ - 107Peer-reviewed studyGaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society. 1964;86:1646–1647. doi:10.1021/ja01062a046
https://doi.org/10.1021/ja01062a046 - 108International agencyWorld Health Organization Expert Committee on Drug Dependence. Cannabidiol (CBD): Critical Review Report. 40th meeting, Geneva, June 2018.
https://cdn.who.int/media/docs/default-source/controlled-substances/whocbdreportmay2018-2.pdf - 109Peer-reviewed reviewRusso EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344–1364. PMID 21749363
https://pubmed.ncbi.nlm.nih.gov/21749363/ - 110Peer-reviewed studyGertsch J, et al. Beta-caryophyllene is a dietary cannabinoid. PNAS. 2008;105(26):9099–9104. PMID 18574142
https://pubmed.ncbi.nlm.nih.gov/18574142/ - 111Randomized controlled trialSpindle TR, et al. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis. Drug and Alcohol Dependence. 2024;257:111267. PMID 38498958
https://pubmed.ncbi.nlm.nih.gov/38498958/ - 112Peer-reviewed reviewNachnani R, Raup-Konsavage WM, Vrana KE. The Pharmacological Case for Cannabigerol. Journal of Pharmacology and Experimental Therapeutics. 2021;376(2):204–212. PMID 33168643
https://pubmed.ncbi.nlm.nih.gov/33168643/ - 113Randomized controlled trialCuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports. 2024;14:16163. PMID 39003387
https://pubmed.ncbi.nlm.nih.gov/39003387/ - 114Peer-reviewed reviewCorroon J. Cannabinol and Sleep: Separating Fact from Fiction. Cannabis and Cannabinoid Research. 2021;6(5):366–371. PMID 34468204
https://pubmed.ncbi.nlm.nih.gov/34468204/ - 115Randomized controlled trialBonn-Miller MO, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology. 2024;32(3):277–284. PMID 37796540
https://pubmed.ncbi.nlm.nih.gov/37796540/ - 116Randomized controlled trialJadoon KA, et al. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes. Diabetes Care. 2016;39(10):1777–1786. PMID 27573936
https://pubmed.ncbi.nlm.nih.gov/27573936/ - 117Randomized controlled trialEnglund A, et al. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers. Journal of Psychopharmacology. 2016;30(2):140–151. PMID 26577065
https://pubmed.ncbi.nlm.nih.gov/26577065/ - 118Historical archiveGeorge Washington's Mount Vernon. George Washington Grew Hemp.
https://www.mountvernon.org/george-washington/farming/washingtons-crops/george-washington-grew-hemp - 119Primary-source compilationCommon Sense for Drug Policy. Nixon Tapes Show Roots of Marijuana Prohibition: Misinformation, Culture Wars and Prejudice (excerpts of declassified 1971–72 Oval Office tapes). March 2002.
https://www.csdp.org/research/shafernixon.pdf - 120Federal law21 U.S.C. § 812 — Schedules of controlled substances (Schedule I criteria and list).
https://www.law.cornell.edu/uscode/text/21/812 - 121Government memoCole JM, Deputy Attorney General. Memorandum for All United States Attorneys: Guidance Regarding Marijuana Enforcement. U.S. Department of Justice, August 29, 2013.
https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf - 122Government memoSessions JB, Attorney General. Memorandum for All United States Attorneys: Marijuana Enforcement. U.S. Department of Justice, January 4, 2018.
https://www.justice.gov/archives/opa/press-release/file/1022196/dl?inline= - 123Presidential statementStatement from President Biden on Marijuana Reform. The White House, October 6, 2022.
https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2022/10/06/statement-from-president-biden-on-marijuana-reform/ - 124Government press releaseU.S. Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III. April 2026.
https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana - 125Research centerPew Research Center. Most Americans now live in a legal marijuana state – and most have at least one dispensary in their county. Feb 29, 2024.
https://www.pewresearch.org/short-reads/2024/02/29/most-americans-now-live-in-a-legal-marijuana-state-and-most-have-at-least-one-dispensary-in-their-county/ - 126Research center (survey)Pew Research Center. Most Americans favor legalizing marijuana for medical, recreational use. Mar 26, 2024.
https://www.pewresearch.org/politics/2024/03/26/most-americans-favor-legalizing-marijuana-for-medical-recreational-use/ - 127Research center (FBI data)Gramlich J. Four-in-ten U.S. drug arrests in 2018 were for marijuana offenses – mostly possession. Pew Research Center, Jan 22, 2020.
https://www.pewresearch.org/short-reads/2020/01/22/four-in-ten-u-s-drug-arrests-in-2018-were-for-marijuana-offenses-mostly-possession/ - 128Industry reportVangst. 2025 Cannabis Jobs Report (press release via PR Newswire, May 13, 2025).
https://www.prnewswire.com/news-releases/cannabis-industry-revenue-grows-whilst-jobs-slightly-stall-vangst-jobs-report-finds-302453501.html - 129Randomized controlled trialLavender IG, et al. Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial. Journal of Sleep Research. 2026;35(4):e70284. PMID 41698831
https://pubmed.ncbi.nlm.nih.gov/41698831/ - 130Federal lawPublic Law 119-103, Continuing Appropriations and Extensions Act, 2027, Sec. 2019 ("Section 781 Extension"). Approved Sept. 2, 2026. GovInfo.
https://www.govinfo.gov/content/pkg/PLAW-119publ103/html/PLAW-119publ103.htm - 131Congress.govH.R. 6500, Continuing Appropriations and Extensions Act, 2027. Bill status: signed by the President and became Public Law 119-103 on Sept. 2, 2026.
https://www.congress.gov/bill/119th-congress/house-bill/6500/all-actions - 132White HouseThe White House. Congressional Bill H.R. 6500 Signed into Law. Sept. 2, 2026.
https://www.whitehouse.gov/briefings-statements/2026/09/congressional-bill-h-r-6500-signed-into-law/ - 133Congressional Research ServiceCongressional Research Service. Delay in Changes to Hemp Definition: Cannabinoids Not Capable of Being Naturally Produced by the Cannabis Plant (LSB11496).
https://www.everycrsreport.com/reports/LSB11496.html - 134NewsMarijuana Moment. Trump Signs Bill To Delay Hemp THC Product Ban, Giving Lawmakers More Time To Craft Regulations Instead Of Prohibition. Sept. 3, 2026.
https://www.marijuanamoment.net/trump-signs-bill-to-delay-hemp-thc-product-ban-giving-lawmakers-more-time-to-craft-regulations-instead-of-prohibition/ - 135NewsNPR (Frank Morris, KCUR). Some states get a head start on upcoming federal hemp ban. Nov. 12, 2026.
https://www.npr.org/2026/11/12/nx-s1-6035839/some-states-get-a-head-start-on-upcoming-federal-hemp-ban - 136Peer-reviewed studyElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency Over the Last 2 Decades (1995–2014): Analysis of Current Data in the United States. Biological Psychiatry. 2016;79(7):613–619. PMID 26903403
https://pubmed.ncbi.nlm.nih.gov/26903403/ - 137Journalism (campaign-finance records)Hamilton K. Here's who bankrolls the fight against marijuana legalization. VICE News, Oct 26, 2016.
https://www.vice.com/en/article/heres-who-bankrolls-the-fight-against-marijuana-legalization/ - 138Journalism (campaign-finance records)Fang L. GOP Mogul Behind Drug Rehab 'Torture' Centers Is Bankrolling Opposition to Pot Legalization in Colorado. The Nation, Sep 18, 2012.
https://www.thenation.com/article/archive/gop-mogul-behind-drug-rehab-torture-centers-bankrolling-opposition-pot-legalization-colo/ - 139Journalism (public records)Mower L, Glorioso A. Donors gave big to DeSantis' marijuana campaign after getting $10M from Hope Florida. Miami Herald / Herald-Times Tallahassee Bureau, Apr 11, 2025.
https://www.miamiherald.com/news/politics-government/article304020886.html - 140Journalism (federal lobbying disclosures)Angell T. Alcohol Industry Steps Up Lobbying On Hemp Drinks As Congress Debates THC Ban. Marijuana Moment, Oct 21, 2025.
https://www.marijuanamoment.net/alcohol-industry-steps-up-lobbying-on-hemp-drinks-as-congress-debates-thc-ban/ - 141JournalismJaeger K. Alcohol Industry Groups Push Congress To Ban Intoxicating Hemp Products—At Least Until Federal Regulations Are Enacted. Marijuana Moment, Nov 4, 2025.
https://www.marijuanamoment.net/alcohol-industry-groups-push-congress-to-ban-intoxicating-hemp-products-at-least-until-federal-regulations-are-enacted/ - 142Video (primary source)American Bridge 21st Century (@American_Bridge). Post and 52-second video of then-Rep. Marsha Blackburn (R-TN) in a hotel lobby, June 8, 2018.
https://x.com/American_Bridge/status/1005155869372403712 - 143Opinion (cites Center for Responsive Politics)Pfeffer AN. Marsha Blackburn cares more about drug sellers than Tennesseans torn by opioid crisis. Knox News / Knoxville News Sentinel, March 12, 2018. Cites Center for Responsive Politics: $711,385 in campaign contributions from the pharmaceutical industry since 2002; also $15,000 from McKesson and $17,500 from Cardinal Health.
https://www.knoxnews.com/story/opinion/columnists/2018/03/12/opinion-marsha-blackburn-cares-more-drug-sellers-than-tennesseans-torn-opioid-crisis/400950002/ - 144News (Associated Press)Schroeder O. Blackburn says it would be 'absurd' to return pharma money. Associated Press, Oct. 27, 2017. Reports a Tennessean review finding at least $96,000 since 2012 from PACs affiliated with or representing the largest opioid manufacturers and distributors, and quotes Blackburn calling questions about returning the money “absolutely absurd.”
https://apnews.com/general-news-ebf0e71b0c2747538e4e7be7021c4319 - 145Investigative journalismHigham S, Bernstein L. The drug industry’s triumph over the DEA. The Washington Post and CBS 60 Minutes, Oct. 15, 2017.
https://www.washingtonpost.com/graphics/2017/investigations/dea-drug-industry-congress/ - 146News (cites campaign-finance records)Sohn P. Marsha Blackburn's opioid sleight of hand. Chattanooga Times Free Press, Oct. 17, 2017. Reports Blackburn received $120,000 in campaign contributions from the pharmaceutical industry between 2013 and June 2017, in the context of the Washington Post / 60 Minutes investigation.
https://www.timesfreepress.com/news/2017/oct/17/sohn-marshblackburns-opioid-sleight-hand/ - 147Fact-checkGreenberg J. Phil Bredesen says Marsha Blackburn weakened DEA opioid enforcement. PolitiFact, Sept. 18, 2018. Reports drug-distributor donations to Blackburn of $6,000 in 2012, rising to $22,000 a few years later, and just shy of $1.3 million in lobbying in 2014–2016 by two distribution companies and the Healthcare Distribution Alliance on the bill she championed.
https://www.politifact.com/factchecks/2018/sep/18/phil-bredesen/bredesen-blackburn-weakened-dea-opioid-enforcement/ - 148Campaign-finance databaseOpenSecrets. Pharmaceuticals/Health Products recipients, Senate, all cycles. Lists Marsha Blackburn (R-TN) at $1,361,176 from PACs and individuals giving $200 or more. Page states figures are for the 1990–2024 election cycles based on FEC data released March 20, 2023.
https://www.opensecrets.org/industries/summary?cycle=All&ind=H04&mem=Y&recipdetail=S